This first-in-class ASO replicates the protective effects of naturally occurring CD33 loss-of-function variants, which are associated with increased resilience to neurodegenerative disease, reduced ...
Ionis is planning a supplemental submission by the end of the year to expand Tryngolza into severe hypertriglyceridemia. If ...
MedPage Today on MSN
Triglyceride-Lowering Drug Gets FDA Nod for Rare Genetic Disorder
The small interfering RNA (siRNA) therapy, designed to reduce triglyceride levels by suppressing production of apolipoprotein ...
With a fresh FDA endorsement for its drug plozasiran, California-based Arrowhead Pharmaceuticals has successfully broken ...
The first few patients have received doses of an experimental RNA-targeting drug for Huntington's disease, it was announced today. The trial aims to test the safety of an experimental drug known as ...
TipRanks on MSN
Veritas In Silico Partners with Shimane University for Post-Transplant Drug Development
Veritas In Silico Inc. ( ($JP:130A) ) has shared an update. Veritas In Silico Inc. has announced a joint research project with Shimane University ...
Grant Zeng, CFA Bio-Path Holdings, Inc. ( BPTH)is a development stage biotech company. The Company was founded with technology from The University of Texas, MD Anderson Cancer Center dedicated to ...
Although amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). are very different diseases, they have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback